Sarcoidosis following alemtuzumab treatment for multiple sclerosis

被引：25

作者：

Willis, Mark D. ^{[1
,2
,3
]}

Hope-Gill, Ben ^{[4
]}

Flood-Page, Patrick ^{[5
]}

Joseph, Fady ^{[6
]}

Needham, Ed ^{[7
]}

Jones, Joanne ^{[7
]}

Coles, Alasdair ^{[7
]}

Robertson, Neil P. ^{[1
,2
,3
]}

机构：

[1] Cardiff Univ, Inst Psychol Med & Clin Neurosci, Heath Pk, Cardiff CF14 4XN, S Glam, Wales

[2] Univ Hosp Wales, Heath Pk, Cardiff CF14 4XN, S Glam, Wales

[3] Univ Hosp Wales, Dept Neurol, Cardiff, S Glam, Wales

[4] Univ Hosp Llandough, Dept Resp Med, Llandough, Wales

[5] Royal Gwent Hosp, Dept Resp Med, Newport, Gwent, Wales

[6] Royal Gwent Hosp, Dept Neurol, Newport, Gwent, Wales

[7] Addenbrookes Hosp, Dept Neurol, Cambridge, England

来源：

MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷 / 13期

关键词：

Multiple sclerosis; alemtuzumab; IMMUNE RECONSTITUTION;

D O I：

10.1177/1352458518790391

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Despite proven efficacy of alemtuzumab in multiple sclerosis (MS), approximately 50% of individuals will develop a new autoimmune disease following treatment. To date, these have largely been antibody mediated and organ specific (primarily affecting the thyroid gland). In a retrospective case series of 187 patients from two UK specialist centres (Cardiff and Cambridge) followed up for a median of 10 years, we report three (1.6%) cases of sarcoidosis following alemtuzumab treatment of MS. This report increases the spectrum of auto-inflammatory disease following alemtuzumab and should be considered by clinicians when using this therapeutic agent for MS.

引用

页码：1779 / 1782

页数：4

共 50 条

[41] Alemtuzumab for multiple sclerosis
不详
LANCET, 2012, 380 (9856): : 1792 - 1792
[42] Alemtuzumab for multiple sclerosis
Riera, Rachel
Porfirio, Gustavo J. M.
Torloni, Maria R.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (04):
[43] Alemtuzumab for Multiple Sclerosis
Mark D. Willis
Neil P. Robertson
Current Neurology and Neuroscience Reports, 2016, 16
[44] Alemtuzumab for multiple sclerosis
Riera, Rachel
Torloni, Maria Regina
Martimbianco, Ana Luiza C.
Pacheco, Rafael L.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2023, (06):
[45] Alemtuzumab in Multiple Sclerosis
Azzopardi, Laura
Coles, Alasdair
NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, 2011, 48 : 79 - 82
[46] Alemtuzumab for Multiple Sclerosis
Willis, Mark D.
Robertson, Neil P.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2016, 16 (09)
[47] Autoimmune Hepatitis During Treatment of Multiple Sclerosis with Alemtuzumab
Carlson, Aaron
Bozinov, Nina
Kipp, Lucas
Dunn, Jeffrey
Lock, Christopher
NEUROLOGY, 2018, 90
[48] Magnetisation transfer imaging of alemtuzumab treatment of multiple sclerosis
Button, T.
Altmann, D.
Tozer, D.
Dalton, C.
Compston, D. A. S.
Miller, D.
Coles, A. J.
MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S437 - S437
[49] Alemtuzumab Immunotherapy of Treatment-Refractory Multiple Sclerosis
Hunter, Samuel F.
Hunter, Heli M.
Brown, Janet M.
Eby, Leiah C.
NEUROLOGY, 2009, 72 (11) : A359 - A359
[50] Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis
Costelloe, Lisa
Jones, Joanne
Coles, Alastair
EXPERT REVIEW OF NEUROTHERAPEUTICS, 2012, 12 (03) : 335 - 341

← 1 2 3 4 5 →